Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,548,587 papers from all fields of science
Search
Sign In
Create Free Account
guanazodine
Known as:
perhydroazocin-2-ylmethylguanidine
, guanidinomethyl-1-monoazacyclooctane
, 2-guanidinomethylheptamethyleneimine
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Guanethidine
Narrower (1)
Sanegit
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1978
1978
[Determination of guanazodine and guanetidin in Sanegyt and Sanotensin preparations].
E. Zöllnerné Iván
Acta pharmaceutica Hungarica
1978
Corpus ID: 20477427
1978
1978
Determination of guanazodine and guanetidin in Sanegyt and Sanotensin preparations
E. ZöllnernéIván
1978
Corpus ID: 99554060
1977
1977
[The influence of guanazodine and todralazine on blood pressure regulation during dynamic and static exercise in essential hypertension (author's transl)].
W. Reiterer
,
H. Czitober
Arzneimittel-Forschung
1977
Corpus ID: 27913559
1976
1976
[Pharmacological effects of [(octahydro-2-azocinyl)methyl] guanidine(guanazodine): its action mechanism and hypotensive effect].
T. Shimizu
,
H. Hamakawa
,
T. Tozuka
,
H. Ono
Nihon yakurigaku zasshi. Folia pharmacologica…
1976
Corpus ID: 25774144
Cardiovascular effects of guanazodine, a new antihypertensive drug, in anesthetized dogs, rabbits and rats and also isolated…
Expand
1976
1976
Effect on carbohydrate metabolism of hypotensive adrenergic neurone blocking agents.
G. Pogátsa
,
A. Káldor
,
B. Gachályi
Acta medica Academiae Scientiarum Hungaricae
1976
Corpus ID: 24777857
In subjects with normal metabolism sugar tolerance was not appreciable influenced by 4 or 5-day courses of guanethidine and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE